Phuong Khanh Morrow - May 23, 2022 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
Chief Medical Officer
Signature
/s/ Elizabeth Ryland Waldinger
Stock symbol
CRSP
Transactions as of
May 23, 2022
Transactions value $
$0
Form type
4
Date filed
5/24/2022, 05:55 PM
Next filing
Oct 12, 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Restricted Stock Units Award $0 +27.8K $0.00 27.8K May 23, 2022 Common Shares 27.8K Direct F1, F2
transaction CRSP Stock Option (Right to Buy) Award $0 +90K $0.00 90K May 23, 2022 Common Shares 90K $54.71 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F2 This restricted stock unit award was granted on May 23, 2022 with respect to 27,750 Common Shares, with (i) one quarter of the shares vesting on May 23, 2023, (ii) one quarter of the shares vesting on May 23, 2024, (iii) one quarter of the shares vesting on May 23, 2025, and (iv) one quarter of the shares vesting on May 23, 2026.
F3 This option was granted on May 23, 2022 with respect to 90,000 Common Shares, with 25% of the shares vesting on May 23, 2023 and the remaining shares vesting on each monthly anniversary thereafter for a period of 36 months.